keyword
MENU ▼
Read by QxMD icon Read
search

Nab paclitaxel

keyword
https://www.readbyqxmd.com/read/29221990/molecular-and-cellular-mechanisms-of-chemoresistance-in-pancreatic-cancer
#1
REVIEW
Aleksandra Adamska, Omar Elaskalani, Aikaterini Emmanouilidi, Minkyoung Kim, Norbaini Binti Abdol Razak, Pat Metharom, Marco Falasca
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most chemoresistant cancers, and current therapies targeting cancer-associated molecular pathways have not given satisfactory results, owing in part to rapid upregulation of alternative compensatory pathways. Most of the available treatments are palliative, focussing on improving the quality of life. At present, available options are surgery, embolization, radiation, chemotherapy, immunotherapy and use of other more targeted drugs. In this review, we describe the cellular and molecular effects of current chemotherapy drugs such as gemcitabine, FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, irinotecan, and leucovorin) and ABRAXANE (nab-Paclitaxel), which have shown a survival benefit, although modest, for pancreatic cancer patients...
November 22, 2017: Advances in Biological Regulation
https://www.readbyqxmd.com/read/29221445/study-protocol-of-hgcsg1404-snow-study-a-phase-i-ii-trial-of-combined-chemotherapy-of-s-1-nab-paclitaxel-and-oxaliplatin-administered-biweekly-to-patients-with-advanced-gastric-cancer
#2
Yasuyuki Kawamoto, Yoshito Komatsu, Satoshi Yuki, Kentaro Sawada, Tetsuhito Muranaka, Kazuaki Harada, Hiroshi Nakatsumi, Hiraku Fukushima, Atsushi Ishiguro, Masayoshi Dazai, Kazuteru Hatanaka, Michio Nakamura, Ichiro Iwanaga, Minoru Uebayashi, Susumu Sogabe, Yoshimitsu Kobayashi, Takuto Miyagishima, Kota Ono, Naoya Sakamoto, Yuh Sakata
BACKGROUND: In Japan, S-1 plus cisplatin (SP) regimen has become a standard therapy for patients with advanced gastric cancer. Moreover, the S-1 plus oxaliplatin regimen is now a standard treatment. Nab-paclitaxel was developed for chemotherapy of gastric cancer in Japanese clinical practice. Nab-paclitaxel, created with albumin-bound paclitaxel particles, has high transferability to tumour tissues and does not cause hypersensitivity reactions because of a different chemical composition compared with docetaxel and paclitaxel...
December 8, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29199705/outcomes-in-lung-cancer-an-experience-from-routine-tertiary-care-setting
#3
R Thippeswamy, S Patil, P Prashanth, C T Sateesh, T Vittal, H P Shashidhara, K M Haridas
BACKGROUND: The aim of this study was to establish characteristics of lung cancer patients diagnosed at a tertiary care hospital in Bangalore. METHODS: The retrospective study was undertaken comprising of 202 patients diagnosed of advanced lung cancer in a tertiary care setting. Data was analyzed to identify patients' characteristics, smoking history, tumor histology, stage of the disease, treatment received, and survival rates. RESULTS: Among the 202 patients diagnosed, 134 were males, and 68 were females...
January 2017: Indian Journal of Cancer
https://www.readbyqxmd.com/read/29190925/nab-paclitaxel-plus-s-1-in-advanced-pancreatic-adenocarcinoma-npspac-a-single-arm-single-center-phase-ii-trial
#4
Yan Shi, Sui Zhang, Quanli Han, Jie Li, Huan Yan, Yao Lv, Huaiyin Shi, Rong Liu, Guanghai Dai
This single-arm, phase II trial is to investigate efficacy and safety of nab-paclitaxel plus S-1 as first-line treatment in advanced pancreatic cancer. Nab-paclitaxel was administered at 120 mg/m2 intravenously on day 1 and 8, S-1 was given twice a day orally on day 1-14 of each 21-day cycle, for 6 cycles. The primary endpoint was objective response rate (ORR), the secondary endpoints were progression-free survival (PFS), overall survival (OS) and safety. The ORR in intent-to-treat population (N=60) by either blinded independent review (BIR) or investigator assessment was 50...
November 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29181169/retrospective-analysis-of-single-agent-nab-paclitaxel-in-patients-with-platinum-resistant-non-small-cell-lung-cancer
#5
Aya Nakaya, Takayasu Kurata, Takashi Yokoi, Yuki Takeyasu, Maiko Niki, Kayoko Kibata, Naoko Satsutani, Yoshitaro Torii, Yuichi Katashiba, Makoto Ogata, Takayuki Miyara, Shosaku Nomura
A retrospective study was conducted to investigate the efficacy and toxicity of single-agent nab-paclitaxel in 67 patients with platinum-resistant non-small cell lung cancer in Kansai Medical University Hospital from August 2013 to December 2015. Overall, 25% of patients experienced disease progression, 48% exhibited a partial response, 27% had stable disease and 0% had a complete response. The median progression-free survival (PFS) time was 4.8 months and the median overall survival time was 18.2 months. There was no statistically significant difference in PFS between patients with non-squamous carcinoma and squamous carcinoma, or between second-line use and post-second-line use...
November 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29177608/identification-of-educational-gaps-among-oncologists-who-manage-patients-with-pancreatic-cancer
#6
Justin A Barnes, Melissa L Ellis, Sharon Hwang, Joan Emarine, Patti Merwin, Gregory D Salinas, Benjamin L Musher
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDA) is associated with poor outcomes and presents oncologists with a myriad of clinical challenges. This study was conducted to assess oncologists' practice patterns and to identify the greatest areas of need for future PDA continuing medical education (CME) programs. METHODS: Case vignettes have been validated as an effective tool to assess how physicians approach and treat a wide array of diseases. In order to assess practice patterns for resectable, locally advanced unresectable, and metastatic PDA, an online case vignette survey was distributed to practicing medical oncologists...
November 27, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/29172757/systemic-effects-of-angiogenesis-inhibition-alter-pharmacokinetics-and-intratumoral-delivery-of-nab-paclitaxel
#7
Anne Steins, Eva A Ebbing, Marcel C M Pistorius, Cynthia Waasdorp, Kausilia K Krishnadath, Jan Paul Medema, Johanna W Wilmink, Ron A A Mathôt, Maarten F Bijlsma, Hanneke W M van Laarhoven
Angiogenesis is critical to the growth of tumors. Vascularization-targeting agents, with or without cytotoxic drugs, are widely used for the treatment of several solid tumors including esophagogastric adenocarcinoma. However, little is known about the systemic effects of anti-angiogenic therapies and how this affects the pharmacokinetics and intratumoral delivery of cytotoxic agents. In this study, patient-derived xenograft mouse models of esophageal adenocarcinoma were used to identify the effects of DC101, a murine vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, on the pharmacokinetics and the intratumoral uptake of nab-paclitaxel (NPTX)...
November 2017: Drug Delivery
https://www.readbyqxmd.com/read/29167692/prognostic-and-predictive-factors-of-eribulin-efficacy-in-heavily-pretreated-patients-affected-by-metastatic-breast-cancer-correlation-with-tumor-biology-and-previous-therapies
#8
Sabrina Rossi, Alessandra Cassano, Antonia Strippoli, Giovanni Schinzari, Ettore D'Argento, Michele Basso, Carlo Barone
Background: Eribulin mesylate is currently approved in the United States and Europe for the treatment of metastatic breast cancer (MBC). Scope: The objective of this retrospective study is to find specific predictive criteria related to patient or tumor characteristics in order to select patients that might benefit the most from eribulin and define the correct treatment sequence. Findings: Forty-four patients with MBC who received eribulin in third or subsequent lines of therapy in a single Italian center were considered eligible...
2017: Drugs in Context
https://www.readbyqxmd.com/read/29158367/safety-pharmacokinetics-pharmacodynamics-and-antitumor-activity-of-necuparanib-combined-with-nab-paclitaxel-and-gemcitabine-in-patients-with-metastatic-pancreatic-cancer-phase-i-results
#9
Eileen M O'Reilly, James Roach, Paul Miller, Kenneth H Yu, Catherine Tjan, Molly Rosano, Silva Krause, William Avery, Julie Wolf, Keith Flaherty, Darrell Nix, David P Ryan
LESSONS LEARNED: Despite the compelling preclinical rationale of evaluating the genetically engineered heparin derivative, necuparanib, combined with standard therapy in metastatic pancreas adenocarcinoma, the results were ultimately disappointing.Safety was documented, although dose escalation was limited by the number of subcutaneous injections, the potential for skin toxicity (cellulitis), and low-level anticoagulant effect. Nonetheless, the hypothesis of targeting prothrombotic pathways in pancreas adenocarcinoma remains compelling...
November 20, 2017: Oncologist
https://www.readbyqxmd.com/read/29152093/the-role-of-weekly-nanoparticle-albumin-bound-paclitaxel-monotherapy-as-second-line-or-later-treatment-for-advanced-nsclc-in-china
#10
Puyuan Xing, Yixiang Zhu, Ling Shan, Sipeng Chen, Xuezhi Hao, Junling Li
For patients with pretreated advanced non-small cell lung cancer (NSCLC), more effective treatments are unmet. We conducted a study to explore the optimal treatment schedule of nanoparticle albumin bound paclitaxel (Nab-PTX) as a second line or later treatment for advanced NSCLC patients in China. Ninety-eight patients, who had experienced failure of prior treatment and received Nab-PTX monotherapy (130 mg/m(2)) on days 1, 8 of a 21-day cycle were included. The median progression-free survival (PFS) and overall survival (OS) were 4...
October 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/29143916/a-real-world-comparison-of-folfirinox-gemcitabine-plus-nab-paclitaxel-and-gemcitabine-in-advanced-pancreatic-cancers
#11
Ying Wang, Pierre Camateros, Winson Y Cheung
PURPOSE: FOLFIRINOX (FFN), nab-paclitaxel plus gemcitabine (GN), and gemcitabine are three systemic therapies that provide clinically meaningful benefit to patients with unresectable pancreatic cancer (UPC). There are no clinical trials that directly compare the efficacy of all three regimens. In this study, we aim to examine and compare the real-world effectiveness of these treatments. METHODS: Patients diagnosed with UPC who initiated palliative chemotherapy from August 2014 to January 2016 at any one of six cancer centers in British Columbia were identified from the provincial pharmacy...
November 16, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/29139084/common-hepatic-artery-abutment-or-encasement-is-an-adverse-prognostic-factor-in-patients-with-borderline-and-unresectable-pancreatic-cancer
#12
Geoffrey M Kozak, Jeffrey D Epstein, Sandeep P Deshmukh, Benjamin B Scott, Scott W Keith, Harish Lavu, Charles J Yeo, Jordan M Winter
BACKGROUND: Localized and unresectable pancreatic ductal adenocarcinoma (PDA) comprises one third of new diagnoses and includes borderline resectable (BR) and locally advanced (LA) unresectable disease. In a cohort of patients who were treated and followed at a single institution, we assessed clinical and radiographic predictors of outcome. METHODS: The study included 69 consecutive patients with BR or LA PDA. Serial imaging studies were reviewed by both a pancreatic surgeon and a radiologist for vascular abutment or encasement by cancer, and they were recorded...
November 14, 2017: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/29138610/nab-paclitaxel-carboplatin-induction-in-squamous-nsclc-longitudinal-quality-of-life-while-on-chemotherapy
#13
Michael Thomas, David R Spigel, Robert M Jotte, Michael McCleod, Mark A Socinski, Ray D Page, Laurent Gressot, Jeanna Knoble, Oscar Juan, Daniel Morgensztern, Dolores Isla, Edward S Kim, Howard West, Amy Ko, Teng Jin Ong, Nataliya Trunova, Cesare Gridelli
Background: Longitudinal data on the impact of treatment on quality of life (QoL) in advanced non-small cell lung cancer (NSCLC) are limited. In this palliative setting, treatment that does not deteriorate QoL is key. Here we report longitudinal QoL in patients with squamous NSCLC, receiving ≤4 cycles of nab-paclitaxel/carboplatin combination chemotherapy. Methods: Patients received nab-paclitaxel 100 mg/m2 days 1, 8, 15 + carboplatin area under the curve 6 mg•min/mL day 1 (q3w) for four cycles...
2017: Lung Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/29138340/phase-i-study-of-chimeric-antigen-receptor-modified-t-cells-in-patients-with-egfr-positive-advanced-biliary-tract-cancers
#14
Yelei Guo, Kai-Chao Feng, Yang Liu, Zhiqiang Wu, Hanren Dai, Qing-Ming Yang, Yao Wang, Hejin Jia, Weidong Han
PURPOSE: This study is an expanded and parallel clinical trial of epidermal growth factor receptor (EGFR)-specific chimeric antigen receptor-engineered autologous T (CART) cell immunotherapy (NCT01869166) to assess the safety and activity of CART-EGFR cell therapy in EGFR-positive advanced unresectable, relapsed/metastatic biliary tract cancers (BTCs). PATIENTS AND METHODS: Patients with EGFR-positive (>50%) advanced unresectable, relapsed/metastatic BTCs were enrolled...
November 14, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29119276/phase-ib-ii-study-of-gemcitabine-nab-paclitaxel-and-pembrolizumab-in-metastatic-pancreatic-adenocarcinoma
#15
Glen J Weiss, Lisa Blaydorn, Julia Beck, Kirsten Bornemann-Kolatzki, Howard Urnovitz, Ekkhard Schütz, Vivek Khemka
Background A single center phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab (GNP) to evaluate the safety and efficacy in metastatic pancreatic adenocarcinoma (PDAC) was conducted (NCT02331251). Methods PDAC patients (pts) with measurable disease, biopsy proven metastasis, adequate laboratory tests, and KPS ≥ 70% received GNP until progression or toxicity. Safety monitoring, RECIST 1.1, and irRECIST assessments were conducted. Response imaging was performed prior to cycle 4, then every 3 months...
November 8, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/29113659/a-comparative-study-of-neoadjuvant-treatment-with-gemcitabine-plus-nab-paclitaxel-versus-surgery-first-for-pancreatic-adenocarcinoma
#16
Benedetto Ielpo, Riccardo Caruso, Hipolito Duran, Eduardo Diaz, Isabel Fabra, Luis Malavé, Valentina Ferri, Rafael Alvarez, Antonio Cubillo, Carlos Plaza, Sara Lazzaro, Denis Kalivaci, Yolanda Quijano, Emilio Vicente
INTRODUCTION: Neoadjuvant treatment has been reported to prolong survival in patients with potentially resectable pancreatic adenocarcinoma (PA). However, there are currently limited clinical results available using nab-paclitaxel and gemcitabine in PA. This paper compares the oncological results of patients affected by potentially resectable PA who underwent surgery first (SF) versus surgery following neoadjuvant treatment (NAT). METHODS: This is an observational, comparative study whereby data were abstracted from a prospective database of patients affected by PA from 2007 to 2016...
December 2017: Surgical Oncology
https://www.readbyqxmd.com/read/29101359/identification-of-a-peptide-peptide-binding-motif-in-the-coating-of-nab-paclitaxel-nanoparticles-with-clinical-antibodies-bevacizumab-rituximab-and-trastuzumab
#17
John T Butterfield, Hidong Kim, Daniel J Knauer, Wendy K Nevala, Svetomir N Markovic
Antibody directed chemotherapy (ADC) takes advantage of the selectivity of the monoclonal antibody to increase the efficacy of the chemotherapeutic agent, while reducing toxicity. Previously we described three nab-paclitaxel (Abraxane) nanoparticles coated with commercial monoclonal antibodies. Identifying the binding sites responsible for these particles could allow reverse engineering of nab-paclitaxel binding antibodies, creating a modular platform for antibody directed chemotherapeutic nanoparticles. Herein, Biacore surface plasmon resonance is used to identify an antibody binding site, HSA Peptide 40, on human serum albumin with nanomolar affinity for all three monoclonal antibodies...
November 3, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29089791/comparative-effectiveness-and-safety-of-nab-paclitaxel-plus-carboplatin-vs-gemcitabine-plus-carboplatin-in-first-line-treatment-of-advanced-squamous-cell-non-small-cell-lung-cancer-in-a-us-community-oncology-setting
#18
Raja Mudad, Manish B Patel, Sandra Margunato-Debay, David Garofalo, Lincy S Lal
INTRODUCTION: Real-world comparative effectiveness, safety, and supportive care use of nab-paclitaxel plus carboplatin vs gemcitabine plus platinum were analyzed in patients with advanced or metastatic squamous cell non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Patients who received ≥ 1 cycle of first-line nab-paclitaxel plus carboplatin or gemcitabine plus platinum were identified from the Navigating Cancer database. Clinical effectiveness endpoints included overall survival (OS) and time to treatment discontinuation (TTD)...
2017: Lung Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/29083340/nab-paclitaxel-after-docetaxel-hypersensitivity-reaction-case-report-and-literature-review
#19
Benedetta Pellegrino, Daniela Boggiani, Chiara Tommasi, Dante Palli, Antonino Musolino
Taxanes, including paclitaxel and docetaxel, are one of the most active cytotoxic agents in breast cancer  treatment  including  Her-2  positive  subtype characterized  by  aggressive  clinical  and pathological features since the early stage. However, their use is sometimes limited by the occurrence of hypersensivity reactions (HSRs) characterized by erythematous rashes, bronchospasm, respiratory distress, hypotension, and pulmonary edema. Cross-reactions between paclitaxel and docetaxel are described in literature with a rate ranging from 49% to 90%...
October 23, 2017: Acta Bio-medica: Atenei Parmensis
https://www.readbyqxmd.com/read/29071003/successful-treatment-of-cardiac-angiosarcoma-associated-with-disseminated-intravascular-coagulation-with-nab-paclitaxel-a-case-report-and-review-of-the-literature
#20
Kazunori Honda, Masashi Ando, Keiji Sugiyama, Seiichiro Mitani, Toshiki Masuishi, Yukiya Narita, Hiroya Taniguchi, Shigenori Kadowaki, Takashi Ura, Kei Muro
Angiosarcoma of the heart is an uncommon soft tissue sarcoma. A few cases of disseminated intravascular coagulation (DIC) associated with angiosarcoma occurring in various organs, but not the heart, have been reported. Although taxane is commonly used in the treatment of metastatic angiosarcoma, data on the efficacy of nab-paclitaxel for angiosarcoma are limited. Here, we report probably the first case of a patient with primary cardiac angiosarcoma with coexisting DIC who was successfully treated with nab-paclitaxel...
September 2017: Case Reports in Oncology
keyword
keyword
84689
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"